Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $558,850.08 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 14,493 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $38.56, for a total value of $558,850.08. Following the sale, the director directly owned 10,500 shares in the company, valued at approximately $404,880. This represents a 57.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Robert Glassman also recently made the following trade(s):

• On Tuesday, September 15th, Robert Glassman sold 8,667 shares of Pharvaris stock. The stock was sold at an average price of $38.27, for a total transaction of $331,686.09.
• On Wednesday, September 9th, Robert Glassman sold 8,000 shares of Pharvaris stock. The stock was sold at an average price of $37.55, for a total transaction of $300,400.00.

Pharvaris Stock Performance

Pharvaris stock opened at $33.07 on Thursday. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25. The firm’s 50-day moving average is $35.36 and its 200-day moving average is $31.93. The company has a market cap of $2.16 billion, a P/E ratio of -10.84 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, sell-side analysts predict that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

PHVS has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, September 8th. HSBC upgraded Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 target price on shares of Pharvaris in a research note on Monday, September 14th. Wedbush raised their target price on Pharvaris from $42.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Finally, Leerink Partners boosted their price target on shares of Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Pharvaris presently has an average rating of “Moderate Buy” and an average target price of $59.87.

Institutional Trading of Pharvaris

Large investors have recently added to or reduced their stakes in the business. venBio Partners LLC acquired a new position in Pharvaris during the 2nd quarter worth $160,569,809. 5AM Venture Management LLC acquired a new position in shares of Pharvaris during the second quarter valued at $27,581,008. BlackRock Inc. bought a new stake in shares of Pharvaris during the second quarter valued at about $26,677,000. Elmind Capital LP bought a new stake in shares of Pharvaris during the second quarter valued at about $18,180,435. Finally, Seven Fleet Capital Management LP lifted its holdings in Pharvaris by 144.6% in the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after purchasing an additional 457,804 shares during the period.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.